Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ptc Therapeutics (PTCT) Finished Goods (2019 - 2025)

Historic Finished Goods for Ptc Therapeutics (PTCT) over the last 7 years, with Q3 2025 value amounting to $8.6 million.

  • Ptc Therapeutics' Finished Goods rose 146.0% to $8.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.6 million, marking a year-over-year increase of 146.0%. This contributed to the annual value of $8.4 million for FY2024, which is 2745.4% down from last year.
  • According to the latest figures from Q3 2025, Ptc Therapeutics' Finished Goods is $8.6 million, which was up 146.0% from $7.5 million recorded in Q2 2025.
  • Over the past 5 years, Ptc Therapeutics' Finished Goods peaked at $11.6 million during Q4 2023, and registered a low of $5.7 million during Q1 2022.
  • Its 5-year average for Finished Goods is $7.6 million, with a median of $6.9 million in 2021.
  • Its Finished Goods has fluctuated over the past 5 years, first tumbled by 3829.89% in 2021, then soared by 7478.97% in 2023.
  • Ptc Therapeutics' Finished Goods (Quarter) stood at $6.7 million in 2021, then fell by 0.91% to $6.7 million in 2022, then surged by 74.79% to $11.6 million in 2023, then dropped by 27.45% to $8.4 million in 2024, then grew by 2.1% to $8.6 million in 2025.
  • Its Finished Goods stands at $8.6 million for Q3 2025, versus $7.5 million for Q2 2025 and $6.5 million for Q1 2025.